Medical device manufacturer Medtronic (NYSE: MDT) is a healthcare industry stalwart. The company, based in the U.S. and ...

Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.

A summary of current health news highlights a bird flu outbreak in Canada, halted HIV vaccine trials in South Africa, a legal ...

CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Medtronic (MDT – Research Report) today. The company’s shares opened today at ...

Medtronic PLC’s stock fell 7.3% as the worst performer in the S&P 500 on Tuesday after the medical-products company’s ...

Medtronic PLC's stock fell 7% as one of the worst performers in the S&P 500 on Tuesday after the medical-products company's earnings fell slightly short of Wall Street's revenue target despite a third ...

Medtronic beat Wall Street estimates for third-quarter profit on Tuesday, partly helped by demand for its diabetes devices, ...

Medtronic reported Q3 revenue of $8.29 billion, missing estimates, while EPS of $1.39 topped forecasts. The company reaffirmed its FY25 organic growth guidance.